Inhibition of carbonic anhydrase IX: A new strategy against cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 6, 2009, Pages 693-702

  Winum, Jean Yves ^a   Scozzafava, Andrea ^b   Montero, Jean Louis ^a   Supuran, Claudiu T ^b  

^a INSTITUT CHARLES GERHARDT   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anticancer agents; Carbonic anhydrase IX; Enzyme inhibition; Sulfamate; Sulfamide; Sulfonamide

Indexed keywords

1 NAPHTHALENESULFONAMIDE; 1 PENTAFLUOROPHENYLAMIDOINDANE 5 SULFONAMIDE; 1,3 BENZENEDISULFONAMIDE DERIVATIVE; 1,3,4 THIADIAZOLE 2 SULFONAMIDE; 2 BUTYLAMIDOINDANE 5 SULFONAMIDE; 2 NONYLAMIDOINDANE 5 SULFONAMIDE; 4 (2 MERCAPTOPHENYLCARBOXAMIDO)BENZENESULFONAMIDE; 4 AMINOETHYLBENZENESULFONAMIDE; 4 CHLOROPHENYLSULFAMATE; 5 AMINO 1,3,4 THIADIAZOLE 2 SULFONAMIDE; ACETAZOLAMIDE; AMINOBENZOLAMIDE; ANTINEOPLASTIC AGENT; BRINZOLAMIDE; CARBONATE DEHYDRATASE IX INHIBITOR; DICLOFENAMIDE; DIHALOGENATED AMINOBENZOLAMIDE DERIVATIVE; DISULFIDE; DORZOLAMIDE; ETHOXZOLAMIDE; INDANESULFONAMIDE DERIVATIVE; INDISULAM; MAFENIDE; METANILAMIDE; METHAZOLAMIDE; N HYDROXYSULFAMIDE DERIVATIVE; ORTHANILAMIDE; PRASTERONE SULFATE INHIBITOR; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HYPOXIA; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; STRUCTURE ANALYSIS;

EID: 70249151696     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009788680028     Document Type: Review

References (60)

1. Pastorekova, S.; Pastorek, J. Cancer-related carbonic anhydrase isozymes. In Carbonic Anhydrase - Its Inhibitors and Activators; Supuran, C.T., Scozzafava, A., Conway, J.; Eds.; CRC Press, Boca Raton (FL): USA, 2004, pp. 253-280.
2. Supuran, C.T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev., 2003, 23, 146-189.
3. Supuran, C.T.; Scozzafava, A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg. Med. Chem., 2007, 15, 4336-4350.
4. Scozzafava, A.; Mastrolorenzo, A.; Supuran, C.T. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin. Ther. Pat., 2006, 16, 1627.
5. Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem., 2004, 19, 199-229.
6. Pastorek, J., Pastorekova, S., Callebaut, I., Mornon, J.P., Zelnik, V., Opavsky, R., Zatovicova, M., Liao, S., Portetelle, D., Stanbridge, E.J., Zavada, J., Burny, A., Kettmann, R. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and putativehelix-loop-helix DNA binding segment. Oncogene, 1994, 9, 2877-2888.
7. Opavský, R.; Pastorekova, S.; Zelnik, V.; Gibadulinova, A.; Stanbridge, E.J.; Zavada, J.; Kettmann, R.; Pastorek, J. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics, 1996, 33, 480-487.
8. Tureci, O.; Sahin, U.; Vollmar, E.; Siemer, S.; Gottert, E.; Seitz, G.; Parkkila, A.K.; Shah, G.N.; Grubb, J.H.; Pfreundschuh, M.; Sly, W.S. Human carbonic anhydrase XII: cDNA cloning, expression and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cancers. Proc. Natl. Acad. Sci. USA, 1998, 95, 7608-7613.
9. Robertson, N.; Potter, C.; Harris, A.L. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res., 2004, 64, 6160-6165.
10. Wykoff, C.C.; Beasley, N.J.; Watson, P.H.; Turner, K.J.; Pastorek, J.; Sibtain, A.; Wilson, G.D.; Turley, H.; Talks, K.L.; Maxwell, P.H.; Pugh, C.W.; Ratcliffe, P.J.; Harris, A.L. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res., 2000, 60, 7075-7083.
11. Potter, C.P.S.; Harris, A.L. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br. J. Cancer, 2003, 89, 2-7.
12. Thiry, A.; Dogne, J.M.; Masereel, B.; Supuran, C.T. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol. Sci., 2006, 27, 566-573.
13. Pastorekova, S.; Parkkila, S.; Zavada, J. Tumor-associated carbonic anhydrases and their clinical significance. Adv. Clin. Chem., 2006, 42, 167-216.
14. Harris, AL. Hypoxia - a key regulatory factor in tumor growth. Nat. Rev. Cancer, 2002, 2, 38-47.
15. Stubbs, M.; McSheehy, P.M.J.; Griffiths, J.R.; Bashford, C.L. Causes and consequences of tumor acidity and implications for treatment. Mol. Med. Today, 2000, 6, 15-19.
16. Svastova, E.; Hulikova, A.; Rafajova, M.; Zatovicova, M.; Gibadulinova, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C.T.; Pastorek, J.; Pastorekova, S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett., 2004, 577, 439-445.
17. Svastova, E.; Zilka, N.; Zatovicova, M.; Gibadulinova, A.; Ciampor, F.; Pastorek, J.; Pastorekova, S. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp. Cell. Res., 2003, 290, 332-345.
18. Cairns, R.; Papandreou, I.; Denko, N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res., 2006, 4, 61-70.
19. Teicher, B.A.; Liu, S.D.; Liu, J.T.; Holden, S.A.; Herman, T.S. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res., 1993, 13, 1549-1556.
20. Chegwidden, W.R.; Spencer, I.M. Sulphonamide inhibitors of carbonic anhydrase inhibit the growth of human lymphoma cells in culture. Inflammopharmacology, 1995, 3, 231-239.
21. Supuran, C.T. ; Briganti, F. ; Tilli, S. ; Chegwidden, W.R.; Scozzafava, A. Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents? Bioorg. Med. Chem., 2001, 9, 703-714.
22. Casini, A.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C.T. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr. Cancer Drug Targets, 2002, 2, 55-75.
23. Scozzafava, A.; Owa, T.; Mastrolorenzo, A.; Supuran, C.T. Anticancer and antiviral sulfonamides. Curr. Med. Chem., 2003, 10, 925-953.
24. Supuran, C.T. Indisulam: an anticancer sulfonamide in clinical development. Expert Opin. Investig. Drugs, 2003, 12, 283-287.
25. Abbate, F.; Casini, A.; Owa, T.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett., 2004, 14, 217-223.
26. Vullo, D.; Franchi, M.; Gallori, E.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C.T. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett., 2003, 13, 1005-1009.
27. Ilies, MA.; Vullo, D.; Pastorek, J.; Scozzafava, A.; Ilies, M.; Caproiu, M.T.; Pastorekova, S.; Supuran, C.T. Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogeno-sulfanilamide and halogenophenylaminobenzolamide derivatives. J. Med. Chem., 2003, 46, 2187-2196.
28. Franchi, M.; Vullo, D.; Gallori, E.; Pastorek, J.; Russo, A.; Scozzafava, A.; Pastorekova, S.; Supuran, C.T. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with lipophilic sulfonamides. J. Enzyme Inhib. Med. Chem., 2003, 18, 333-338.
29. Pastorekova, S.; Casini, A.; Scozzafava, A.; Vullo, D.; Pastorek, J.; Supuran, C.T. Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett., 2004, 14, 869-873.
30. Garaj, V.; Pucetti, L.; Fasolis, G.; Winum, J-Y.; Montero, J-L.; Scozzafava, A.; Vullo, D.; Innocenti, A.; Supuran, C.T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/ tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg. Med. Chem. Lett., 2004, 14, 5427-5433.
31. Garaj, V.; Pucetti, L.; Fasolis, G.; Winum, J-Y.; Montero, J-L.; Scozzafava, A.; Vullo, D.; Innocenti, A.; Supuran, C.T. Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg. Med. Chem. Lett., 2005, 15, 3102-3108.
32. Scozzafava, A.; Menabuoni, L.; Mincione, F.; Briganti, F.; Mincione, G.; Supuran, C. T. Carbonic anhydrase inhibitors: perfluoro-alkyl/ aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. J. Med. Chem., 2000, 43, 4542-4551.
33. Di Fiore, A.; De Simone, G.; Menchise, V.; Pedone, C.; Casini, A.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors: X-ray crystal structure of a benzenesulfonamide strong CA II and CA IX inhibitor bearing a pentafluorophenylaminothioureido tail in complex with isozyme II. Bioorg. Med. Chem. Lett., 2005, 15, 1937-1942.
34. Vullo, D.; Scozzafava, A.; Pastorekova, S.; Pastorek, J.; Supuran, C.T. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. Bioorg. Med. Chem. Lett., 2004, 14, 2351-2356.
35. Cecchi, A.; Taylor, S.D.; Liu, Y.; Hill, B.; Vullo, D.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors: Inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg. Med. Chem. Lett., 2005, 15, 5192-5196.
36. Puccetti, L.; Fasolis, G.; Vullo, D.; Chohan, Z.H.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors. Inhibition of cytosolic/ tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes. Bioorg. Med. Chem. Lett. 2005, 15, 3096-3101.
37. Puccetti, L.; Fasolis, G.; Cecchi, A.; Winum, J-Y.; Gamberi, A.; Montero, J-L.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds. Bioorg. Med. Chem. Lett., 2005, 15, 2359-2464.
38. Ozensoy, O.; Puccetti, L.; Fasolis, G.; Arslan, O.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg. Med. Chem. Lett., 2005, 15, 4862-4866.
39. Cecchi, A.; Winum, J-Y.; Innocenti, A.; Vullo, D.; Montero, J-L.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide. Bioorg. Med. Chem. Lett., 2004, 14, 5775-5780.
40. Innocenti, A.; Villar, R.; Martinez-Merino, V.; Gil, M.J.; Scozzafava, A.; Vullo, D.; Supuran, C.T. Carbonic anhydrase inhibitors: Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides. Bioorg. Med. Chem. Lett., 2005, 15, 4872-4876.
41. Winum, J. Y.; Dogne, J. M.; Casini, A.; de Leval, X.; Montero, J. L.; Scozzafava, A.; Vullo, D.; Innocenti, A.; Supuran, C.T. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties. J. Med. Chem., 2005, 48, 2121-2125.
42. Thiry, A.; Ledecq, M.; Cecchi, A.; Dogné, J.M.; Wouters, J.; Supuran, C.T.; Masereel, B. Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J. Med. Chem., 2006, 49, 2743-2749.
43. Winum, J.Y.; Cecchi, A.; Montero, J-L.; Innocenti, A.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: Toward agents for boron neutron capture therapy of hypoxic tumors. Bioorg. Med. Chem. Lett., 2005, 15, 3302-3306.
44. Winum, J.Y.; Scozzafava, A.; Montero, J.L.; Supuran, C.T. New zinc binding motifs in the design of selective carbonic anhydrase inhibitors. Mini Rev. Med. Chem., 2006, 6, 921-936.
45. Winum, J.Y.; Scozzafava, A.; Montero, J.L.; Supuran, C.T. Therapeutic applications of sulfamates. Expert Opin. Ther. Pat., 2004, 14, 1273-1308.
46. Winum, J.Y.; Scozzafava, A.; Montero, J.L.; Supuran, C.T. Sulfamates and their therapeutic potential. Med. Res. Rev., 2005, 25, 186-228.
47. Winum, J.Y.; Scozzafava, A.; Montero, J.L.; Supuran, C.T. The sulfamide motif in the design of enzyme inhibitors. Expert Opin. Ther. Pat., 2006, 16, 27-47.
48. Winum, J.Y.; Scozzafava, A.; Montero, J.L.; Supuran, C.T. Therapeutic potential of sulfamides as enzyme inhibitors. Med. Res. Rev., 2006, 26, 767-792.
49. Winum, J.Y.; Vullo, D.; Casini, A.; Montero, J-L.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J. Med. Chem., 2003, 46, 2197-2204.
50. Nussbaumer, P.; Billich, A. Steroid sulfatase inhibitors. Med. Res. Rev., 2004, 24, 529-576.
51. Nussbaumer, P.; Billich, A. Steroid sulfatase inhibitors: their potential in the therapy of breast cancer. Curr. Med. Chem. Anticancer Agents, 2005, 5, 507-528.
52. Winum, J.Y.; Vullo, D.; Casini, A.; Montero, J.L.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J. Med. Chem., 2003, 46, 5471-5477.
53. Winum, J.Y.; Pastorekova, S.; Jakubickova, L.; Montero, J.L.; Scozzafava, A.; Pastorek, J.; Vullo, D.; Innocenti, A.; Supuran, C.T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/ tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg. Med. Chem. Lett., 2005, 15, 579-584.
54. Briganti, F.; Pierattelli, A.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors 37. Novel classes of isozyme I and II inhibitors and their mechanism of action. Kinetic and spectroscopic investigations on native and cobalt-substituted enzymes. Eur. J. Med. Chem., 1996, 31, 1001-1010.
55. Casini, A.; Winum, J-Y.; Montero, J-L.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors: Inhibition of cytosolic isozymes I and II with sulfamide derivatives. Bioorg. Med. Chem. Lett., 2003, 13, 837-840.
56. Winum, J-Y.; Innocenti, A.; Nasr, J.; Montero, J-L.; Scozzafava, A.; Vullo, D.; Supuran, C.T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxysulfamides - a new zinc-binding function in the design of inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 2353-2358.
57. Denny, W.A. Hypoxia-activated anticancer drugs. Expert Opin. Ther. Pat., 2005, 15, 635-646.
58. Boyle, R.G.; Travers, S. Hypoxia: targeting the tumour. Anticancer Agents Med. Chem., 2006, 6, 281-286.
59. Saczewski, F.; Slawinski, J.; Kornicka, A.; Brzozowski, Z.; Pomarnacka, E.; Innocenti, A.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. Bioorg. Med. Chem. Lett., 2006, 16, 4846-4851.
60. De Simone, G.; Vitale, R.M.; Di Fiore, A.; Pedone, C.; Scozzafava, A.; Montero, J.L.; Winum, J.Y.; Supuran, C.T. Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J. Med. Chem., 2006, 49, 5544-5551.